Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.
Alan L HoIrene BranaRobert I HaddadJessica BaumanKeith C BibleSjoukje OostingDeborah J WongMyung-Ju AhnValentina BoniCaroline EvenJerome FayetteMaria José FlorKevin J HarringtonSung-Bae KimLisa F LicitraIoanna NixonNabil F SabaStephan HackenbergPol SpecenierFrancis WordenBinaifer BalsaraMollie LeoniBridget MartellCatherine ScholzAntonio GualbertoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Tipifarnib demonstrated encouraging efficacy in patients with R/M HNSCC with HRAS mutations for whom limited therapeutic options exist (NCT02383927).
Keyphrases